Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Patients whose Type 2 diabetes is not controlled with metformin can benefit long-term from a two-drug combination treatment that also reduces weight.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.